You have   6 free profiles   left this month    Start Your Free Trial ➤
Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there? View on RelSci Pro ➤

Michael Shalmi

Managing Director, Principal Investments at Novo Holding A/S
In The News
Career History
Boards & Committees

Michael Shalmi

Managing Director, Principal Investments at Novo Holding A/S


53 (Born 1965)
Board Seats
Number of Relationships
This person is connected to 311 people.

Relationships See Details

Advisor at VF Venture

Executive Chairman at Orexo AB

Chief Executive Officer & Director at Momentum Gruppen A/S

Former Chief Financial Officer at Novo Holding A/S

Co-Founder at Aerocrine AB

Founding Partner at HealthCap AB

Group Chief Executive Officer at Synlab International GmbH

Senior Director Principal Investments at Novo Holding A/S

Former Chief Executive Officer at Novo Holding A/S

President & Chief Executive Officer at Novo Holding A/S
See 301 more listings with RelSci Professional.

In The News See More

Business Wire
August 10, 2017
Business Wire
June 14, 2017
Business Wire
May 10, 2017
ENP Newswire
April 13, 2017
April 12, 2017
See full news coverage and complete stories with RelSci Professional.

Paths to Michael Shalmi

Michael Shalmi
Connections via Relationship Science
Michael Shalmi
Sync your contacts to see how you can connect with Michael Shalmi.

Educational Background

With over 40,000 students and more than 9,000 employees, the University of Copenhagen is the largest institution of research and education in Denmark. The purpose of the University – to quote the University Statute – is to ’conduct research and provide further education to the highest academic level’.
Watching SIMI - Scandinavian International Management Institute.

Career History

Managing Director
2009 - Current
Novo Large Investments is an active, long-term manager which invests in successful later-stage private and publicly listed life science companies (with a bias towards late-clinical and early commercial stage product-focused companies). Their geographic focus is on companies in Denmark, Europe and North America.The firm acts as venture catalysts, investing later in the life cycle of promising life science companies, aiming to catalyze their value by providing ongoing support in the form of constructive advice and access to their network, insight and capabilities until tangible results materialize.Novo Large Investments typically invests USD 20-50 million in companies based on unique science which promote compelling, commercially relevant products and which are driven by insightful leadership, and have the ability to go substantially higher when required. They prefer to take significant minority stakes in their investee companies.
Managing Director, Principal Investments
Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation’s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.
Chief Medical Officer, BioPharm
2008 - 2009
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care; and Biopharmaceuticals segments. The Diabetes and Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Boards & Committees

Corporate Boards ▾
Member-Supervisory Board
2017 - Current
Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the EVT Execute and EVT Innovate segments. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include research fees, milestones and royalties. The EVT Innovate segment focuses on building a longterm partnered pharmaceutical pipeline from its own, internally developed assets and platforms. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
2014 - Current
Aerocrine AB engages in the sale of medical technology products that are used to facilitate the diagnosis and improve the treatment and monitoring of patients with airway inflammation. It offers NIOX Flex and NIOX MINO, which are tools to assist in the diagnosis and control of airways disease. The company operates through the North America or USA and EU or the Rest of the World segments. Aerocrine was founded by Lars Gustafsson, Jon Lundberg and Eddie Weitzberg in November 1997 and is headquartered in Solna, Sweden.
Member, Board of Directors
2010 - Current
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. Its focuses on the treatment of opioid dependence. It distributes its products under the following brands: Zubsolv, Abstral, and Edluar. The company was founded by Thomas Lundqvist, Anders Pettersson, and Lars Christer Nyström on November 18, 1994 and is headquartered in Uppsala, Sweden.
Synlab International GmbH provides laboratory diagnostics for human and veterinary medicine and environmental analysis services. The firm offers medical instruments, transfusion medicines, cytology, pathology, human genetics, and general hygiene services. The company was founded by Bartl Wimmer in 1998 and is headquartered in Munich, Germany.
Momentum Gruppen A/S provides and administrates solar and wind projects. It specializes in procuring, disseminating, and managing solar and wind projects. The firm caters both small and private investors, as well major investment funds and pension funds. The company was founded by Kim Madsen in 2005 and is headquartered in Roskilde, Denmark.

Other Affiliations

You've reached your 7 free profiles limit this month.

Upgrade to RelSci Pro today to enjoy unlimited profile views and much more!

Start My Free Trial
Still not convinced? Check out our full listing of features here.